Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Do docetaxel nanoparticles boost response in mCRPC?

Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

Key clinical point: A docetaxel-encapsulating nanoparticle targeted against prostate-specific membrane antigen (PSMA) was safe and showed good activity in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) .

Major finding: The 6-month progression-free survival rate, the primary endpoint, was 65%.

Study details: Open-label, phase 2 trial of 42 men with mCRPC that progressed on abiraterone acetate and/or enzalutamide.

Disclosures: The study was funded by BIND Therapeutics and by grants from the National Institutes of Health, Sidney Kimmel Center for Prostate and Urologic Cancers, and the David H. Koch Prostate Cancer Research Fund. Dr. Autio had no disclosures. Several coauthors are employees of BIND Therapeutics, and others are employed by Epic Sciences, maker of the CTC assay used in the study. Other coauthors reported advising/consulting, research support, and speakers bureau activities for multiple companies.

Source: Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

Read the article.

Citation:

Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in Genitourinary Cancer

Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10

Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.

Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002

Radioactive agent approved for adrenal tumors, FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma.